146 related articles for article (PubMed ID: 38427960)
1. Neoadjuvant Peptide Receptor Radionuclide Therapy in a Rare Case of Pediatric Primary Hepatic Gastrinoma.
Mahato S; Aggarwal P; Thunga C; Sood A; Kanojia RP; Nada R; Lal SB
Clin Nucl Med; 2024 Apr; 49(4):e161-e163. PubMed ID: 38427960
[TBL] [Abstract][Full Text] [Related]
2. The State of Peptide Receptor Radionuclide Therapy and Its Sequencing among Current Therapeutic Options for Gastroenteropancreatic Neuroendocrine Tumors.
Raymond LM; Korzun T; Kardosh A; Kolbeck KJ; Pommier R; Mittra ES
Neuroendocrinology; 2021; 111(11):1086-1098. PubMed ID: 33744879
[TBL] [Abstract][Full Text] [Related]
3. Neoadjuvant peptide receptor radionuclide therapy for an inoperable neuroendocrine pancreatic tumor.
Kaemmerer D; Prasad V; Daffner W; Hörsch D; Klöppel G; Hommann M; Baum RP
World J Gastroenterol; 2009 Dec; 15(46):5867-70. PubMed ID: 19998512
[TBL] [Abstract][Full Text] [Related]
4. Predictors of long-term outcome in patients with well-differentiated gastroenteropancreatic neuroendocrine tumors after peptide receptor radionuclide therapy with 177Lu-octreotate.
Ezziddin S; Attassi M; Yong-Hing CJ; Ahmadzadehfar H; Willinek W; Grünwald F; Guhlke S; Biersack HJ; Sabet A
J Nucl Med; 2014 Feb; 55(2):183-90. PubMed ID: 24434296
[TBL] [Abstract][Full Text] [Related]
5. Peptide receptor radionuclide therapy as neoadjuvant therapy for resectable or potentially resectable pancreatic neuroendocrine neoplasms.
Partelli S; Bertani E; Bartolomei M; Perali C; Muffatti F; Grana CM; Schiavo Lena M; Doglioni C; Crippa S; Fazio N; Zamboni G; Falconi M
Surgery; 2018 Apr; 163(4):761-767. PubMed ID: 29284590
[TBL] [Abstract][Full Text] [Related]
6. Performance of 177Lu-DOTATATE-based peptide receptor radionuclide therapy in metastatic gastroenteropancreatic neuroendocrine tumor: a multiparametric response evaluation correlating with primary tumor site, tumor proliferation index, and dual tracer imaging characteristics.
Thapa P; Ranade R; Ostwal V; Shrikhande SV; Goel M; Basu S
Nucl Med Commun; 2016 Oct; 37(10):1030-7. PubMed ID: 27243215
[TBL] [Abstract][Full Text] [Related]
7. Peptide receptor radionuclide therapy as a potential tool for neoadjuvant therapy in patients with inoperable neuroendocrine tumours (NETs).
Sowa-Staszczak A; Pach D; Chrzan R; Trofimiuk M; Stefańska A; Tomaszuk M; Kołodziej M; Mikołajczak R; Pawlak D; Hubalewska-Dydejczyk A
Eur J Nucl Med Mol Imaging; 2011 Sep; 38(9):1669-74. PubMed ID: 21559978
[TBL] [Abstract][Full Text] [Related]
8. Surgical Feasibility, Determinants, and Overall Efficacy of Neoadjuvant
Parghane RV; Bhandare M; Chaudhari V; Ostwal V; Ramaswamy A; Talole S; Shrikhande SV; Basu S
J Nucl Med; 2021 Nov; 62(11):1558-1563. PubMed ID: 33637590
[TBL] [Abstract][Full Text] [Related]
9. Peptide Receptor Radionuclide Therapy in the Treatment of Neuroendocrine Tumors.
Kwekkeboom DJ; Krenning EP
Hematol Oncol Clin North Am; 2016 Feb; 30(1):179-91. PubMed ID: 26614376
[TBL] [Abstract][Full Text] [Related]
10. Quality of Life in Patients with Metastatic Gastroenteropancreatic Neuroendocrine Tumors Receiving Peptide Receptor Radionuclide Therapy: Information from a Monitoring Program in Clinical Routine.
Martini C; Buxbaum S; Rodrigues M; Nilica B; Scarpa L; Holzner B; Virgolini I; Gamper EM
J Nucl Med; 2018 Oct; 59(10):1566-1573. PubMed ID: 30042164
[TBL] [Abstract][Full Text] [Related]
11. Prospective study of somatostatin receptor scintigraphy and its effect on operative outcome in patients with Zollinger-Ellison syndrome.
Alexander HR; Fraker DL; Norton JA; Bartlett DL; Tio L; Benjamin SB; Doppman JL; Goebel SU; Serrano J; Gibril F; Jensen RT
Ann Surg; 1998 Aug; 228(2):228-38. PubMed ID: 9712569
[TBL] [Abstract][Full Text] [Related]
12. Primary hepatic gastrinoma, extremely rare case presentation and its surgical resolution, in a third level hospital in Mexico.
González-López R; Ramírez-Castañeda J; Ortega-Jiménez JA; García-Cano E; Palacios-Rojo M; Núñez-González RA; Sosa-Luis AS; Gutiérrez-Quiroz CT
Cir Cir; 2022; 90(1):109-113. PubMed ID: 35120102
[TBL] [Abstract][Full Text] [Related]
13. Neoadjuvant strategies for advanced pancreatic neuroendocrine tumors: should combined chemotherapy and peptide receptor radionuclide therapy be the preferred regimen for maximizing outcome?
Basu S; Parghane RV; Ostwal V; Shrikhande SV
Nucl Med Commun; 2018 Jan; 39(1):94-95. PubMed ID: 29206780
[No Abstract] [Full Text] [Related]
14. Peptide receptor radionuclide therapy in gastroenteropancreatic NEN G3: a multicenter cohort study.
Carlsen EA; Fazio N; Granberg D; Grozinsky-Glasberg S; Ahmadzadehfar H; Grana CM; Zandee WT; Cwikla J; Walter MA; Oturai PS; Rinke A; Weaver A; Frilling A; Gritti S; Arveschoug AK; Meirovitz A; Knigge U; Sorbye H
Endocr Relat Cancer; 2019 Feb; 26(2):227-239. PubMed ID: 30540557
[TBL] [Abstract][Full Text] [Related]
15. Resistant functioning and/or progressive symptomatic metastatic gastroenteropancreatic neuroendocrine tumors: efficacy of 177Lu-DOTATATE peptide receptor radionuclide therapy in this setting.
Kalshetty A; Ramaswamy A; Ostwal V; Basu S
Nucl Med Commun; 2018 Dec; 39(12):1143-1149. PubMed ID: 30308585
[TBL] [Abstract][Full Text] [Related]
16. Biochemically curative surgery for gastrinoma in multiple endocrine neoplasia type 1 patients.
Imamura M; Komoto I; Ota S; Hiratsuka T; Kosugi S; Doi R; Awane M; Inoue N
World J Gastroenterol; 2011 Mar; 17(10):1343-53. PubMed ID: 21455335
[TBL] [Abstract][Full Text] [Related]
17. Peptide Receptor Radionuclide Therapy Using 177Lu-DOTATATE: Nursing Roles in Managing Patients With Gastroenteropancreatic Neuroendocrine Tumors.
Bennett B; Gardner L; Ryan P
Clin J Oncol Nurs; 2024 Jan; 28(1):79-87. PubMed ID: 38252861
[TBL] [Abstract][Full Text] [Related]
18. Symptomatic and Radiological Response to 177Lu-DOTATATE for the Treatment of Functioning Pancreatic Neuroendocrine Tumors.
Zandee WT; Brabander T; Blažević A; Kam BLR; Teunissen JJM; Feelders RA; Hofland J; de Herder WW
J Clin Endocrinol Metab; 2019 Apr; 104(4):1336-1344. PubMed ID: 30566620
[TBL] [Abstract][Full Text] [Related]
19. The value of somatostatin-receptor scintigraphy in newly diagnosed endocrine gastroenteropancreatic tumors.
Kisker O; Bartsch D; Weinel RJ; Joseph K; Welcke UH; Zaraca F; Rothmund M
J Am Coll Surg; 1997 May; 184(5):487-92. PubMed ID: 9145069
[TBL] [Abstract][Full Text] [Related]
20. An esophageal gastrointestinal stromal tumor in a patient with MEN1-related pancreatic gastrinoma: an unusual association and review of the literature.
Massironi S; Rossi RE; Ferrero S; Cavalcoli F; Spampatti MP; Conte D; Corbetta S; Peracchi M
J Cancer Res Ther; 2014; 10(2):443-5. PubMed ID: 25022420
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]